Inluriyo (Imlunestrant) Dosage and Usage

Inluriyo (Imlunestrant) is a new oral selective estrogen receptor degrader (SERD), suitable for the treatment of estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer with ESR1 mutations. With its precise mechanism of action and convenient oral route, this drug provides a new treatment option for patients who are resistant to endocrine therapy.

The recommended dose of Inluriyo is 400 mg taken orally once daily and should be taken on an empty stomach. The specific requirements are: take the medicine at least 2 hours before a meal or 1 hour after a meal to avoid food interference on the drug absorption rate and blood drug concentration. Patients should swallow the tablets whole and do not break, crush or chew the tablets to ensure complete drug release and stable bioavailability.

Treatment with Inluriyo should be continued until disease progression or the patient experiences unacceptable toxicity. If mild to moderate adverse reactions occur during treatment, symptomatic treatment or short-term discontinuation of the drug can be carried out under the guidance of a doctor; if the adverse reactions are serious, permanent discontinuation of the drug or a change of treatment plan should be considered.

If the patient accidentally misses a dose, the missed dose should be taken as soon as possible; however, if the next dose is less than 12 hours away, the missed dose should be skipped and do not double the dose at one time to make up for the missed dose. Regular medication is essential to maintain the steady-state blood concentration of the drug, which helps ensure the persistence of therapeutic effects and the stability of disease control.

During treatment, patients should follow the habit of taking medication at a fixed time, and can choose to take it at a fixed time every morning or evening to improve compliance. At the same time, it is recommended to cooperate with regular imaging and laboratory examinations to evaluate the efficacy and monitor safety indicators. Doctors should flexibly adjust treatment strategies based on the patient's overall condition, tumor response, and tolerance.

Reference materials:https://www.drugs.com/inluriyo.html